ArticleThe clinical respiratory journal2026
Role of α-SMA, NOX4, Fibronectin, and HIF-1α in Pulmonary Microvascular Remodeling in COPD Patients Without Pulmonary Arterial Hypertension.
Article in The clinical respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPulmonary arterial hypertension (PAH) is a severe chronic obstructive pulmonary disease (COPD) complication, with vascular remodeling occurring early in disease progression. Oxidative stress, particularly NADPH oxidase subunit 4 (NOX4) activity, drives vascular smooth muscle differentiation, vasoconstriction, and proliferation, while Hypoxia-inducible factor-1α (HIF-1α), activated by NOX4-derived hydrogen peroxide (H
methodsLung tissue samples from patients undergoing resection at General Hospital of Ningxia Medical University (Oct 2022-Dec 2023) were analyzed. Participants included COPD (n = 20) and control (n = 17) groups. NOX4, HIF-1α, α-SMA, and fibronectin expression in the pulmonary microvasculature (< 500 μm) were assessed via immunohistochemistry and Western blot. Smooth muscle remodeling (pulmonary vascular smooth muscle thickness percentage, WT%; pulmonary vascular smooth muscle area percentage, WA%) and serum vascular endothelial growth factor (VEGF) levels were evaluated.
resultsCOPD patients exhibited significant thickening of the pulmonary microvascular smooth muscle layer, with endothelial cell swelling, degeneration, and necrosis. The WT% and WA% values of COPD patients were elevated compared to controls, alongside increased FN expression in the pulmonary microvasculature. NOX4, HIF-1α, and α-SMA expression levels were higher in COPD patients, particularly within endothelial cells and macrophages surrounding pulmonary vessels. The peripheral blood neutrophil count in the COPD group was higher than in the control group. Compared to the control group, COPD patients showed high expression of NOX4 and HIF-1α in macrophages surrounding the pulmonary microvessels. Serum VEGF concentrations were significantly elevated in COPD patients and positively correlated with HIF-1α expression in lung tissue homogenates.
conclusionsPulmonary microvascular remodeling occurs in COPD patients even without PAH, characterized by smooth muscle thickening, extracellular matrix deposition, and endothelial alterations. The NOX4-HIF-1α oxidative stress pathway, coupled with inflammatory cell activation, may contribute to microvascular remodeling in COPD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.